Clinical Trial Update: A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C [Phase 1]

View source ↗

Summary

A Phase 1 trial comparing pharmacokinetics of belatacept from two manufacturing processes (Process E vs Process C) in renal transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• belatacept (active pharmaceutical ingredient from both Process E and Process C) (belatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Renal Transplantation | Phase 1 | Status: COMPLETED | Results posted: 2019-04-17